Clinical trials: Pegfilgrastim
Breast Cancer
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
This is a study of dose dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel (Taxol; T) with pegfilgrastim (Neulasta) and darbepoetin alfa support in the adjuvant breast cancer setting.
- Trial name
- NCT00261313
- Testing
- Neulasta, Aranesp
- Volunteers
- 80 people
- Sponsor
- Amgen
Non Hodgkin Lymphoma, Breast Cancer
Patient Preference for Pegfilgrastim (Neulasta®) Application Forms
The study aims to compare two application forms (pre-filled syringe and On-body injector) of the same active drug (pegfilgrastim) in adult patients under chemotherapy regarding patient preference and health economics.
- Trial name
- CONVENIENCE (NCT03619993)
- Testing
- On-body injector, Pre-filled syringe
- Where
- 48 sites in Germany
- Volunteers
- 404 people
- Sponsor
- iOMEDICO AG
Localized Breast Cancer
Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration
Patients including of localized breast cancer will require chemotherapy treatment with epirubicin - cyclophosphamide (EC) followed by treatment with docetaxel or paclitaxel.
- Trial name
- EMEG-ECDD (NCT05296317)
- Testing
- Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim), Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
- Where
- France
- Volunteers
- 97 people
- Sponsor
- Centre Georges Francois Leclerc
Breast Cancer, Triple Negative Breast Cancer
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
This is a phase II single-arm, open-label, prospective study to evaluate the efficacy of the low dose weekly Carboplatin/Paclitaxel followed by dose-dense Doxorubicin/Cyclophosphamide in subjects with triple-negative breast…
- Trial name
- NCT03301350
- Testing
- Carboplatin, Paclitaxel, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Wisconsin, Madison
Locally Advanced Pancreatic Cancer, Pancreatic Cancer
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10…
- Trial name
- NCT02578732
- Testing
- FOLFOXA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Brown University
Breast Cancer, Lymphoma
Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain
Purpose: To evaluate the preventative effects of pregabalin on pegfilgrastim-induced bone pain in cycle 1. Because granulocyte colony stimulating factor (G-CSF) receptors are found at nerve endings which modulate the pain signal…
- Conditions
- Breast Cancer, Lymphoma, Pain
- Trial name
- NCT03407430
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
HER2-negative Breast Cancer, Stage II Breast Cancer
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00679029
- Testing
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Nebraska
Non-Hodgkin's Lymphoma
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
This is a phase I trial of the combination of bendamustine, rituximab and pixantrone in patients with relapsed/refractory B cell non-Hodgkin lymphoma.
- Trial name
- BRP (NCT01491841)
- Testing
- Bendamustine + Rituximab + Pixantrone, Pegfilgrastim
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Anne Beaven, MD
Bladder Cancer
Stress-reducing Intervention in Urothelial Carcinoma
The aim of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in patients with muscle-infiltrating bladder carcinoma (MIBC) treated with chemotherapy based on cisplatin in…
- Trial name
- NCT06269536
- Testing
- HRV biofeedback
- Where
- Slovakia
- Volunteers
- 50 people
- Sponsor
- Comenius University
DLBCL - Diffuse Large B Cell Lymphoma
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity.
- Trial name
- HO170DLBCL (NCT06220032)
- Testing
- Dexrazoxane, Rituximab, Cyclophosphamide
- Where
- 25 sites in Netherlands
- Volunteers
- 324 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Breast Cancer
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
The purpose of this study is to determine if patient education can affect patient reported bone pain in breast cancer patients receiving chemotherapy and pegfilgrastim.
- Trial name
- VINE (NCT01752907)
- Testing
- General Education DVD, Bone Pain Education DVD
- Where
- 51 sites in United States
- Volunteers
- 304 people
- Sponsor
- Amgen
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
- Trial name
- NCT03907488
- Testing
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography
- Where
- 728 sites in United States, Canada and 1 more
- Volunteers
- 994 people
- Sponsor
- National Cancer Institute (NCI)
Solid Malignancies
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
Hypothesis : pegfilgrastim at 200 µg/kg between 12 and 18 days after previous chemotherapy provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study.
- Trial name
- MEG-5 (NCT00751894)
- Testing
- Pegfilgrastim (Neulasta, Amgen)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Bladder Cancer, Muscle-invasive Bladder Cancer
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients…
- Trial name
- NCT00808639
- Testing
- Methotrexate, Doxorubicin, vinblastine
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Chemotherapy
Various G-CSF Regimens to Prevent Infection During Chemotherapy
The purpose of this study is to prevent chemotherapy-related febrile neutropenia, prophylaxis with antibiotics and granulocyte colony-stimulating factor (G-CSF) have proven efficacious [1-3].
- Conditions
- Breast Cancer, Chemotherapy, Febrile Neutropenia
- Trial name
- NCT00536081
- Testing
- pegfilgrastim
- Where
- 21 sites in Netherlands
- Volunteers
- 172 people
- Sponsor
- Academisch Ziekenhuis Maastricht
Lymphoma
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma
The goal of this clinical research study is to learn if loratadine can control bone pain caused by pegfilgrastim (a drug given after chemotherapy to help raise white blood cell counts).
- Trial name
- NCT02392039
- Testing
- Pegfilgrastim, Loratadine, Questionnaires
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously…
- Trial name
- NCT01533207
- Testing
- Clinical Observation, Docetaxel, Doxorubicin Hydrochloride
- Where
- 623 sites in United States, Belgium and 6 more
- Volunteers
- 38 people
- Sponsor
- Gynecologic Oncology Group
Solid Tumors
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.
- Trial name
- NCT01297452
- Testing
- BKM120 days 1 - 21 plus paclitaxel + carboplatin, BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin, BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy
The purpose of this study is to estimate the relationship between patient reported outcomes (PROs) and neutropenia (or its complications) in NSCLC subjects receiving chemotherapy with or without Neulasta® (pegfilgrastim).
- Trial name
- NCT00115206
- Testing
- Neulasta® (pegfilgrastim)
- Sponsor
- Amgen
Neutropenia
Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer
Pegfilgrastim is a long-acting recombinant human granulocyte-colony stimulating factor as support for chemotherapy, which can be used conveniently.
- Trial name
- NCT05283616
- Testing
- Pegfilgrastim
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences